- Home
- RXRX
as 07-26-2024 4:00pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.3B | IPO Year: | 2021 |
| Target Price: | $13.00 | AVG Volume (30 days): | 5.8M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.97 - $15.74 | Next Earning Date: | 08-06-2024 |
| Revenue: | $46,235,000 | Revenue Growth: | -0.88% |
| Revenue Growth (this year): | 34.81% | Revenue Growth (next year): | 53.53% |
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Borgeson Blake | RXRX | Director | Jul 9 '24 | Sell | $7.32 | 11,447 | $83,734.81 | 7,167,110 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | Jun 25 '24 | Sell | $9.51 | 11,447 | $108,806.02 | 7,177,116 | SEC Form 4 |
| Secora Michael | RXRX | Chief Financial Officer | Jun 13 '24 | Sell | $9.27 | 15,000 | $139,081.50 | 1,267,843 | SEC Form 4 |
| Secora Michael | RXRX | Chief Financial Officer | Jun 13 '24 | Sell | $9.32 | 15,000 | $139,798.50 | 1,243,468 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | Jun 11 '24 | Sell | $8.45 | 11,447 | $96,762.64 | 7,188,563 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Jun 5 '24 | Sell | $9.00 | 50,000 | $450,000.00 | 708,738 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Jun 5 '24 | Sell | $8.42 | 50,000 | $421,000.00 | 758,738 | SEC Form 4 |
| Marriott Tina | RXRX | President and COO | May 30 '24 | Sell | $8.78 | 3,000 | $26,325.00 | 535,457 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | May 28 '24 | Sell | $9.17 | 11,447 | $104,942.66 | 7,186,913 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | May 14 '24 | Sell | $10.12 | 20,054 | $202,934.45 | 7,198,360 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | May 1 '24 | Sell | $7.73 | 50,000 | $386,500.00 | 863,524 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | May 1 '24 | Sell | $8.47 | 28,704 | $243,122.88 | 834,820 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | May 1 '24 | Sell | $8.47 | 21,296 | $180,377.12 | 834,820 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | Apr 30 '24 | Sell | $7.95 | 11,447 | $90,963.59 | 7,218,414 | SEC Form 4 |
| Marriott Tina | RXRX | President and COO | Apr 25 '24 | Sell | $7.67 | 3,000 | $23,020.50 | 543,231 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | Apr 16 '24 | Sell | $7.66 | 11,447 | $87,725.23 | 7,229,861 | SEC Form 4 |
| Secora Michael | RXRX | Chief Financial Officer | Apr 16 '24 | Sell | $7.67 | 25,000 | $191,657.50 | 1,216,679 | SEC Form 4 |
| Secora Michael | RXRX | Chief Financial Officer | Apr 16 '24 | Sell | $7.58 | 23,124 | $175,349.29 | 1,231,055 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Apr 3 '24 | Sell | $8.84 | 40,000 | $353,600.00 | 978,524 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Apr 3 '24 | Sell | $9.02 | 40,000 | $360,800.00 | 938,524 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Apr 3 '24 | Sell | $8.84 | 25,000 | $221,000.00 | 0 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Apr 3 '24 | Sell | $9.02 | 25,000 | $225,500.00 | 0 | SEC Form 4 |
| Borgeson Blake | RXRX | Director | Apr 2 '24 | Sell | $8.82 | 11,447 | $100,941.94 | 7,241,308 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Mar 28 '24 | Sell | $10.10 | 25,000 | $252,500.00 | 0 | SEC Form 4 |
| Gibson Christopher | RXRX | Chief Executive Officer | Mar 28 '24 | Sell | $10.10 | 40,000 | $404,000.00 | 1,043,524 | SEC Form 4 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know
Motley Fool
9 days ago
3 Millionaire-Maker Artificial Intelligence (AI) Stocks
Zacks
10 days ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Motley Fool
13 days ago
Is Recursion Pharmaceuticals Stock a Buy?
Motley Fool
13 days ago
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Motley Fool
15 days ago
These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street
MT Newswires
15 days ago
KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating
Zacks
15 days ago
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.